How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Chinese artificial intelligence start-up MiniMax plans to channel funds from its proposed Hong Kong initial public offering (IPO) into research and development as it seeks to compete with global and ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
SHANGHAI: Two Chinese artificial intelligence (AI) startups seen as possible rivals to OpenAI aim to complete their Hong Kong initial public offerings (IPOs) in the coming weeks. Shanghai-based ...
That said, the exorbitant $1,100 starting price for the 128-gigabyte model is more than most people are comfortable spending on a phone. Plus, its advanced features are overkill for those who need a ...
From the outset, the Minisforum MS-S1 Max is an exciting machine and is designed with a specific user group in mind. It's on the edge of what I would define as a mini PC. It might be smaller than a ...
The Geekom AX8 MAX mini PC presents a strong combination of premium build quality, powerful internal components, and professional-grade performance within an impressively compact footprint. Weighing ...
2-Year U.S. Treasury Note Continuous Contract $104.406 0.023 0.02% 5-Year U.S. Treasury Note Continuous Contract $109.430 0.063 0.06% 10-Year U.S. Treasury Note Continuous Contract $112.688 0.109 0.10 ...
James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback